Aspergillosis R&D Pipeline Analysis Report, Q4 2020
Aspergillosis Pipeline Overview
The Q4 Aspergillosis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Aspergillosis, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.
Aspergillosis Disease Types, Symptoms, Causes, and Available Treatment Options
The comprehensive report on the indication presents Aspergillosis disease overview, Aspergillosis types, Aspergillosis symptoms, causes, and FDA/EMA approved treatment options.
Aspergillosis Pipeline Trends and Insights
The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Aspergillosis indication. The report presents near-term and long-term pipeline development trends and potential insights.
Aspergillosis Company Trends and Insights
The report analyzes the development progress, current status, investments, partnerships, and other developments of 27 companies. Business profiles and contact details of the companies actively perusing Aspergillosis pipeline are assessed.
Aspergillosis R&D Pipeline Development Phase Trends and Insights
From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Aspergillosis discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.
Small Aspergillosis companies look for licensing and collaboration partners
High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Aspergillosis pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.
Aspergillosis Pipeline Market News and Developments during 2020
The Aspergillosis industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.
Aspergillosis Mechanism of Action and Targets
Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.
New molecular entity details
Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.
Sources and Research Methodology
Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.
Scope and Coverage
The Q4 Aspergillosis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Aspergillosis, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.
Aspergillosis Disease Types, Symptoms, Causes, and Available Treatment Options
The comprehensive report on the indication presents Aspergillosis disease overview, Aspergillosis types, Aspergillosis symptoms, causes, and FDA/EMA approved treatment options.
Aspergillosis Pipeline Trends and Insights
The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Aspergillosis indication. The report presents near-term and long-term pipeline development trends and potential insights.
Aspergillosis Company Trends and Insights
The report analyzes the development progress, current status, investments, partnerships, and other developments of 27 companies. Business profiles and contact details of the companies actively perusing Aspergillosis pipeline are assessed.
Aspergillosis R&D Pipeline Development Phase Trends and Insights
From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Aspergillosis discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.
Small Aspergillosis companies look for licensing and collaboration partners
High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Aspergillosis pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.
Aspergillosis Pipeline Market News and Developments during 2020
The Aspergillosis industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.
Aspergillosis Mechanism of Action and Targets
Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.
New molecular entity details
Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.
Sources and Research Methodology
Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.
Scope and Coverage
- Aspergillosis pipeline development activities across the early phase, mid-stage, and late phase pipelines including therapeutic candidates
- Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new molecular entity, area, and other details.
- Company-company partnerships, company-institute partnerships, and investment details of companies are included
- 27 companies are included including Acea Biotech Inc, Amplyx Pharmaceuticals Inc, Argenx SE, Basilea Pharmaceutica Ltd, Biosergen AS, Cellix Bio, Cidara Therapeutics Inc, F2G Ltd, iCo Therapeutics Inc, Immupharma Plc, Matinas BioPharma Holdings Inc, Merck & Co Inc, Molecular Express Inc, Mycovia Pharmaceuticals Inc, Nanomerics Ltd, Novabiotics Ltd, Pulmatrix Inc, Pulmocide Ltd, Regeneron Pharmaceuticals Inc, Scynexis Inc, Sealife PHARMA GMBH, Shaanxi Synthetic Pharmaceutical Co Ltd, Takis, TFF Pharmaceuticals Inc, Trilogy Therapeutics Inc, Visterra Inc, Zambon Co SpA,
- Disease overview, Pipeline trends, market analysis, and other developments
- Potential licensing/new business opportunities in Aspergillosis pipeline market
- Global coverage of companies and pipeline agents
- 2020 Trends, market analysis, and developments
- Potential growth opportunities
- Comprehensive details of drug candidates
- Drive pipeline research and commercial assessment
- Assess most promising drug candidates and stay ahead of the competition
- Strengthen your pipeline through identifying business expansion and acquisition opportunities
- Develop new candidates based on most focused targets and mechanism of actions
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. ASPERGILLOSIS PIPELINE TRENDS AND INSIGHTS
2.1 Dominant Phase type of Aspergillosis Pipeline, 2020
2.2 Most focused Mechanism of Action in Aspergillosis Pipeline
2.3 Leading type of Route of Administration during 2020
2.4 Proportion of New Molecular Entities in Aspergillosis pipeline
2.5 Active Companies Developing Aspergillosis pipeline
3. ASPERGILLOSIS DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS
3.1 Disease Overview
3.2 Types
3.3 Symptoms
3.4 Approved Treatment Options
4. ASPERGILLOSIS PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS
4.1 Acea Biotech Inc
Amplyx Pharmaceuticals Inc
Argenx SE
Basilea Pharmaceutica Ltd
Biosergen AS
Cellix Bio
Cidara Therapeutics Inc
F2G Ltd
iCo Therapeutics Inc
Immupharma Plc
Matinas BioPharma Holdings Inc
Merck & Co Inc
Molecular Express Inc
Mycovia Pharmaceuticals Inc
Nanomerics Ltd
Novabiotics Ltd
Pulmatrix Inc
Pulmocide Ltd
Regeneron Pharmaceuticals Inc
Scynexis Inc
Sealife PHARMA GMBH
Shaanxi Synthetic Pharmaceutical Co Ltd
Takis
TFF Pharmaceuticals Inc
Trilogy Therapeutics Inc
Visterra Inc
Zambon Co SpA
5. ASPERGILLOSIS PIPELINE DRUG PROFILES
5.1 Current Status of Drug and Vaccine Candidates
5.2 Drug Snapshot
5.2.1 Drug
5.2.2 Mechanism of Action
5.2.3 Phase
5.2.4 Co-Developer
5.2.5 Originator
5.2.6 Synonym
5.2.7 Route of Administration
5.2.8 Type of Molecule
5.2.9 Orphan Drug Status
5.2.10 New Molecular Entity
5.2.11 Area
5.3 Drug Details
5.4 Mechanism of Action
5.5 Licensing/Collaboration Agreements
5.6 Clinical Trial Details
6. ASPERGILLOSIS PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020
7. APPENDIX
7.1 About the Publisher
7.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2. ASPERGILLOSIS PIPELINE TRENDS AND INSIGHTS
2.1 Dominant Phase type of Aspergillosis Pipeline, 2020
2.2 Most focused Mechanism of Action in Aspergillosis Pipeline
2.3 Leading type of Route of Administration during 2020
2.4 Proportion of New Molecular Entities in Aspergillosis pipeline
2.5 Active Companies Developing Aspergillosis pipeline
3. ASPERGILLOSIS DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS
3.1 Disease Overview
3.2 Types
3.3 Symptoms
3.4 Approved Treatment Options
4. ASPERGILLOSIS PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS
4.1 Acea Biotech Inc
Amplyx Pharmaceuticals Inc
Argenx SE
Basilea Pharmaceutica Ltd
Biosergen AS
Cellix Bio
Cidara Therapeutics Inc
F2G Ltd
iCo Therapeutics Inc
Immupharma Plc
Matinas BioPharma Holdings Inc
Merck & Co Inc
Molecular Express Inc
Mycovia Pharmaceuticals Inc
Nanomerics Ltd
Novabiotics Ltd
Pulmatrix Inc
Pulmocide Ltd
Regeneron Pharmaceuticals Inc
Scynexis Inc
Sealife PHARMA GMBH
Shaanxi Synthetic Pharmaceutical Co Ltd
Takis
TFF Pharmaceuticals Inc
Trilogy Therapeutics Inc
Visterra Inc
Zambon Co SpA
5. ASPERGILLOSIS PIPELINE DRUG PROFILES
5.1 Current Status of Drug and Vaccine Candidates
5.2 Drug Snapshot
5.2.1 Drug
5.2.2 Mechanism of Action
5.2.3 Phase
5.2.4 Co-Developer
5.2.5 Originator
5.2.6 Synonym
5.2.7 Route of Administration
5.2.8 Type of Molecule
5.2.9 Orphan Drug Status
5.2.10 New Molecular Entity
5.2.11 Area
5.3 Drug Details
5.4 Mechanism of Action
5.5 Licensing/Collaboration Agreements
5.6 Clinical Trial Details
6. ASPERGILLOSIS PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020
7. APPENDIX
7.1 About the Publisher
7.2 Sources and Research Methodology
